What is the risk of breast cancer relapsing after 10 years?

EndoPredict® Breast Cancer Prognostic test provides an accurate assessment for risk of breast cancer recurrence after 10 years, allowing clinicians and their patients to make confident chemotherapy decisions together.1

Information for clinicians

Use EndoPredict to guide early breast cancer treatment decisions

EndoPredict is the only second generation breast cancer prognostic test validated for premenopausal AND postmenopausal women with early-stage breast cancer that is ER positive, HER2 negative, node negative or positive1-7 – and the only second generation test with level of evidence 1A data.8,9

EndoPredict is the most accurate prognostic test to guide early treatment decisions, providing an individual risk for distant recurrence ten years after breast cancer diagnosis. This crucial information helps avoid under and over treatment in all patient subgroups.10

If you are a patient, please ask your doctor if the EndoPredict test is right for you, or visit our patient homepage for more information.

EndoPredict identifies a large patient group at low-risk of breast cancer recurrence at 10 years

In all validation studies of ER positive, HER2 negative, node positive and node negative patients, EndoPredict identified a large low-risk group for recurrent breast cancer after 10 years, with a recurrence risk of less than 10%, regardless whether the patients were pre- or postmenopausal.1-7

The homogenous (solely ER positive, HER2 negative) cohorts used are one reason for the test’s stronger performance compared to tests that included HER2 positive patients in their training cohorts. The score and the cut-off value are consistent in all studies and have never changed.

EndoPredict identifies women with a true low-risk of recurrent breast cancer after 10 years

Compared to risk stratification using only clinical parameters or other gene expression tests, EndoPredict identifies a large group of true low-risk breast cancer patients who could avoid chemotherapy.4,7,10

In node positive patients, EndoPredict was one of the two signatures that identified patients with true low risk of distant recurrence (<10%) at 10 years.

Learn more about EndoPredict in node positive patients.

EndoPredict is the only second generation breast cancer recurrence test with level of evidence 1A data9

Initial results from a randomized controlled prospective phase III study (UNIRAD) released at SABCS 2021 prospectively confirm the validation studies.8

A prospective French registry (SiMoSein) with more than 4,700 patients presented at ESMO 2021 emphasizes the clinical need for gene expression testing to avoid over and under treatment.11

EndoPredict outperforms other gene expression tests for breast cancer recurrence at 10 years

EndoPredict is the most accurate prognostic test with two clear risk groups across 10 years compared to first generation AND second generation breast cancer recurrence tests.10

EndoPredict is validated across premenopausal women and other subgroups at 10 years

Premenopausal breast cancer

Studies show that regardless of nodal status, EndoPredict detects premenopausal patients who are true low-risk that may safely avoid chemotherapy.2,12

Nodal status

EndoPredict illuminates the right treatment pathway for every woman, regardless of nodal status or number of positive lymph nodes.

How does the EndoPredict breast cancer test work?

The EndoPredict animated app can show you how various gene activities in the tumor influence the prognosis and how the molecular fingerprint and tumor size and nodal status contribute to the final EndoPredict result.

EndoPredict second generation test can be performed locally within a few days

EndoPredict Breast Cancer Prognostic Test is available to order by clinicians via numerous local labs in your country or outside of the EU also via Myriad Genetics’ central laboratory in Salt Lake City, USA.

References

  1. Filipits, Martin et al. “A New Molecular Predictor Of Distant Recurrence In ER-Positive, HER2-Negative Breast Cancer Adds Independent Information To Conventional Clinical Risk Factors“. Clinical Cancer Research, vol 17, no. 18, 2011, pp. 6012-6020
  2. Constantinidou, Anastasia, et al. “Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer”. Clinical Cancer Research, vol. 28, no. 20, 2022, pp. 4435–4443
  3. Filipits, Martin et al. “Prediction Of Distant Recurrence Using Endopredict Among Women With ER+, HER2− Node-Positive And Node-Negative Breast Cancer Treated With Endocrine Therapy Only“. Clinical Cancer Research, vol 25, no. 13, 2019, pp. 3865-3872
  4. Buus, Richard et al. “Comparison Of Endopredict And Epclin With Oncotype DX Recurrence Score For Prediction Of Risk Of Distant Recurrence After Endocrine Therapy“. Journal Of The National Cancer Institute, vol 108, no. 11, 2016, p. djw149
  5. Sestak, Ivana et al. “Prediction Of Chemotherapy Benefit By Endopredict In Patients With Breast Cancer Who Received Adjuvant Endocrine Therapy Plus Chemotherapy Or Endocrine Therapy Alone“. Breast Cancer Research And Treatment, vol 176, no. 2, 2019, pp. 377-386
  6. Martin, Miguel et al. “Clinical Validation Of The Endopredict Test In Node-Positive, Chemotherapy-Treated ER+/HER2− Breast Cancer Patients: Results From The GEICAM 9906 Trial“. Breast Cancer Research, vol 16, no. 2, 2014, p. R38
  7. Dubsky, Peter et al. “The Endopredict Score Provides Prognostic Information On Late Distant Metastases In ER+/HER2− Breast Cancer Patients“. British Journal Of Cancer, vol 109, no. 12, 2013, pp. 2959-2964
  8. Penault-Llorca, Frederique et al. “Prognostic value of EndoPredict test in patients screened for UNIRAD, a UCBG randomized, double blind, phase III international trial evaluating the addition of *** (EVE) to adjuvant hormone therapy (HT) in women with high risk HR+, HER2- early breast cancer (eBC)“. SABCS 2021, PD-09-08 Spotlight Poster Discussion 9
  9. Simon, Richard et al. “Use Of Archived Specimens In Evaluation Of Prognostic And Predictive Biomarkers”. Journal Of The National Cancer Institute, vol 101, no. 21, 2009, pp. 1446-1452
  10. Sestak, Ivana et al. “Comparison Of The Performance Of 6 Prognostic Signatures For Estrogen Receptor–Positive Breast Cancer“. JAMA Oncology, vol 4, no. 4, 2018, pp. 545-553
  11. Lehmann-Che, Jacqueline et al. “Simosein, A Real-Life Prospective Evaluation Of Endopredict Use In Early ER-Positive, HER2-Negative Breast Cancers“. Annals Of Oncology, vol 32, 2021, p. 430
  12. Vázquez-Juarez, Daniela et al. ”Follow-up of prospective cohort of Mexican premenopausal women with breast cancer who received guided adjuvant treatment with the EndoPredict assay.” SABCS 2021, P4-05-15